RCS - OptiBiotix Health - OptiBiotix obtains BRC accreditation

OptiBiotix HealthAnnouncement

05/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220105:nRSE4249Xa&default-theme=true

RNS Number : 4249X  OptiBiotix Health PLC  05 January 2022

    OptiBiotix Health plc

("OptiBiotix" or the "Company" or the "Group")

 

OptiBiotix obtains British Retail Consortium accreditation

One of the leading international food safety standards

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing unique
science and human study-based compounds that modulate the microbiome to
address metabolic syndrome and diabetes, systemic low-grade inflammation,
obesity, cardiovascular disease, high cholesterol and to support healthy aging
has achieved British Retail Consortium ('BRC') accreditation.

 

BRC was the first standard to meet the Global Food Safety Initiative ('GFSI')
benchmark, which means it is accepted by many of the world's biggest
retailers, such as Tesco and Walmart. The certification ensures customers have
confidence in OptiBiotix's products and it allows the Company to do business
with those retailers, manufacturers, ingredients companies and food service
organisations who specify certification as part of their approval process
(most large retailers and their suppliers). It incorporates food safety
management systems and internationally accepted best practice to ensure the
safety and quality of products and in doing so reduces the risk of recalls.

 

René Kamminga, CEO of OptiBiotix Limited, commented: "We are very pleased
to announce our BRC accreditation which supports our commercial strategy of
selling final product solutions to partners in the retail channel containing
our science backed pro and prebiotic ingredients. I am particularly proud of
our team which achieved this accreditation in a relatively short period of
time."

 

For further information, please contact:

 

 OptiBiotix Health plc                                  www.optibiotix.com (http://www.optibiotix.com/)
 Stephen O'Hara, Chief Executive  Contact via Walbrook below

 Cenkos Securities plc (Broker)                         Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                        Mob: 07876 741 001
 Anna Dunphy

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASSUFWLEESEFF